https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-08 / Clin. Immunol. 2009 Apr;131(1):1-10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-08 / Clin. Immunol. 2009 Apr;131(1):1-102009-02-08 00:00:002019-02-15 09:23:57FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-01 / Acta Oncol 2009;48(3):452-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-01 / Acta Oncol 2009;48(3):452-62009-01-01 00:00:002009-01-01 00:00:00Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-01 / Urol. Oncol. 2008 Nov-Dec;26(6):576-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-01 / Urol. Oncol. 2008 Nov-Dec;26(6):576-802008-11-01 00:00:002019-02-15 09:23:59Dendritic cell vaccines for the treatment of prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-08-01 / J Biomech Eng 2008 Aug;130(4):041016
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-08-01 / J Biomech Eng 2008 Aug;130(4):0410162008-08-01 00:00:002019-02-15 10:00:35A two-state cell damage model under hyperthermic conditions: theory and in vitro experiments
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-18 / Genet Vaccines Ther 2008 Jan;6:2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-18 / Genet Vaccines Ther 2008 Jan;6:22008-01-18 00:00:002019-02-15 09:24:02Therapeutic dendritic cell vaccine preparation using tumor RNA transfection: a promising approach for the treatment of prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-14 / Urol. Oncol. 2009 Jan-Feb;27(1):26-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-14 / Urol. Oncol. 2009 Jan-Feb;27(1):26-322008-01-14 00:00:002019-02-15 09:23:59Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-01 / BioDrugs 2008;22(2):71-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-01 / BioDrugs 2008;22(2):71-842008-01-01 00:00:002019-02-15 09:24:01Prostate cancer vaccines: current status and future potential
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-12-21 / Urol. Oncol. 2008 Jul-Aug;26(4):438-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-12-21 / Urol. Oncol. 2008 Jul-Aug;26(4):438-442007-12-21 00:00:002019-02-15 09:24:00Immunotherapy for metastatic prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-11-26 / Eur. Urol. 2008 Apr;53(4):694-708
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-11-26 / Eur. Urol. 2008 Apr;53(4):694-7082007-11-26 00:00:002019-02-15 09:24:03Advances in specific immunotherapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-08-15 / Cancer Res. 2007 Aug;67(16):7798-806
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-08-15 / Cancer Res. 2007 Aug;67(16):7798-8062007-08-15 00:00:002019-02-15 08:48:34Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity
